Legacy Behavioral Health Center Inc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 233 W Avenue A Ste C, Belle Glade, FL 33430 Phone: 561-253-3679 Fax: 561-253-3680 |
Multilingual Psychotherapy Centers, Inc. Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 233 W Avenue A Ste C, Belle Glade, FL 33430 Phone: 561-253-3679 Fax: 561-253-3680 |
South County Mental Health Center, Inc. Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 808 Nw Avenue D, Belle Glade, FL 33430 Phone: 561-708-8396 Fax: 561-983-8583 |
Tdnt Counseling Services Counselor Medicare: Not Enrolled in Medicare Practice Location: 1340 Nw Ave L #2213, Belle Glade, FL 33430 Phone: 561-292-0220 |
Phoenix Rising Psychotherapy Center Pllc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 816 W Canal St S, Belle Glade, FL 33430 Phone: 561-502-1500 |
Tdnt Social Services, Inc. Counselor Medicare: Not Enrolled in Medicare Practice Location: 1340 Nw Avenue L, #2213, Belle Glade, FL 33430 Phone: 408-956-4728 |
Irecovery, Llc Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 241 Se 1st St, Belle Glade, FL 33430 Phone: 561-464-5500 Fax: 561-464-5501 |
News Archive
Botox, a medication derived from a bacterial toxin, is commonly injected to ease wrinkles, migraines, muscle spasms, excessive sweating and incontinence.
Mylan Inc. today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin.
A new report finds that developing nations' ability to deal with pressing health challenges like HIV/AIDS and ensuring maternal and newborn survival will be strengthened by creating a common definition for community health workers, as well as a core set of skills and competencies that would help ensure they are optimally trained, supported and deployed to provide care and treatment when and where it is needed most.
MAP Pharmaceuticals, Inc. announced today it will present new analyses from the FREEDOM-301 Phase 3 clinical trial in a late breaker session at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California on Friday, June 25 from 3:30 to 4:00 pm PT. The presentation will show that the Company's investigational LEVADEX™ orally inhaled migraine therapy was effective irrespective of when it was administered during a migraine cycle.
To meet the growing demand for its services throughout the Asia-Pacific region, Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today announced the official grand opening of its expanded regional headquarters facility in Singapore's Science Park I.
› Verified 9 days ago